#D-101 AAD 2024 Efficacy of Biologic Therapy in Moderate-to-Severe Psoriasis Dr. Rebecca Chen, Dr. David... Biologic therapy demonstrated 89% reduction in PASI score at week 16 compared to 12% with placebo. Quality of life improved...
#D-102 AAD 2024 Novel Topical JAK Inhibitor for Atopic Dermatitis Treatment Dr. Michael Park, Dr. Jennifer... Topical JAK inhibitor achieved 58% IGA 0/1 response at week 8. Rapid itch relief within 24 hours in majority of...
#D-103 AAD 2024 Immunotherapy for Advanced Melanoma: 5-Year Survival Data Dr. Elizabeth Moore, Dr. Thomas... Five-year overall survival reached 52% with combination immunotherapy vs 34% with monotherapy. Durable responses observed.
#D-104 AAD 2024 Dupilumab Efficacy in Adolescent Atopic Dermatitis Dr. Patricia Johnson, Dr. Mark... Dupilumab achieved clear/almost clear skin in 42% of adolescents by week 16. Significant improvement in itch and quality of life.
#D-105 AAD 2024 Early Intervention in Vitiligo: Outcomes and Predictors Dr. Daniel Garcia, Dr. Michelle... Early treatment within 6 months of onset achieved 75% repigmentation vs 28% for delayed treatment. Facial lesions responded best.
#D-106 AAD 2024 Laser Treatment for Recalcitrant Warts: Comparative Study Dr. Rachel Kim, Dr. Steven... Pulsed dye laser achieved 78% complete clearance vs 41% with cryotherapy. Fewer treatments required with laser.
#D-107 AAD 2024 Oral Minoxidil for Female Pattern Hair Loss Dr. Victoria Turner, Dr. Andrew... Low-dose oral minoxidil increased hair density by 18% at 24 weeks. Patient satisfaction high with minimal side effects.
#D-108 AAD 2024 Rosacea Subtype-Specific Treatment Approaches Dr. Samuel Green, Dr. Laura... Tailored therapy based on rosacea subtype achieved 72% improvement vs 43% with standard approach. Combination therapy most effective.
#D-109 AAD 2024 AI-Assisted Melanoma Detection in Primary Care Dr. Jonathan Scott, Dr. Maria... AI algorithm sensitivity 94% for melanoma detection vs 78% for general practitioners. Specificity 89% vs 85%.
#D-110 AAD 2024 Systemic Therapy for Hidradenitis Suppurativa: Real-World Outcomes Dr. Benjamin Wright, Dr. Catherine... Biologic therapy achieved 63% HiSCR response at 16 weeks in real-world setting. Quality of life improved significantly.